
DLBCL Treatment Merck Begins Phase 3 Trial of Zilovertamab Vedotin
Merck Begins Phase 3 Trial of Zilovertamab Vedotin for DLBCL Treatment DLBCL Treatment Merck known as MSD outside the United States and Canada, has officially announced the initiation of waveLINE-010, a pivotal Phase 3 clinical trial assessing the efficacy and…